| The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia. | |
| | |
MedLine Citation:
|
PMID: 17164750 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression has been suggested to play an important role in the pathogenesis of atherosclerosis. Lipid-lowering therapy with 3-hydroxy-methylglutaryl-coenzyme A reductase inhibitors reduces the incidence of atherosclerosis-related cardiovascular events. The aim of this study was to establish the effect of a 3-month treatment of fluvastatin on circulating (c)ICAM-1 and standard lipid parameters. METHODS: A total of 14 patients (6 men and 8 women), 59.7+/-11 years old, with mean systolic and diastolic blood pressure 135+/-16.3 and 81+/-9.3 mmHg, respectively, fasting plasma cholesterol 6.2+/-1 mmol/L and plasma triglycerides 2.6+/-1 mmol/L, took part in the study. The observed parameters were measured before and after 3 months of therapy. RESULTS: When comparing total cholesterolemia, low-density lipoprotein (LDL) cholesterol, and apolipoprotein B, there were significant decreases after a 3-month treatment. By contrast, no significant difference was observed when we compared the values of triglycerides, high-density lipoprotein (HDL) cholesterol, apolipoprotein A1 and, especially, of cICAM-1. Our results demonstrate the well-known capacity of fluvastatin to lower LDL- and total cholesterol; however, it failed to reduce cICAM after a 3-month treatment. CONCLUSIONS: It can be concluded that a 3-month therapy with fluvastatin does not decrease cICAM-1 levels, despite normalization of cholesterol levels. The implication is that cholesterol may not induce endothelial activation by the initial upregulation of this adhesive molecule. |
| | |
Authors:
|
T Sejda; V Jedlièková; E Svandová; R Poledne |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International angiology : a journal of the International Union of Angiology Volume: 25 ISSN: 0392-9590 ISO Abbreviation: Int Angiol Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2006-12-13 Completed Date: 2007-06-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8402693 Medline TA: Int Angiol Country: Italy |
Other Details:
|
Languages: eng Pagination: 414-7 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine I, Thomayer University Hospital, Prague, Czech Republic. tomas.sejda@ftn.cz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers Dyslipidemias / physiopathology* Endothelium, Vascular / physiopathology* Fatty Acids, Monounsaturated / pharmacology* Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology* Indoles / pharmacology* Intercellular Adhesion Molecule-1 / biosynthesis*, drug effects* Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 126547-89-5/Intercellular Adhesion Molecule-1; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular...
Next Document: Brachial endothelial function in subjects with familial combined hyperlipidemia and its relationship...